Navigation Links
BioSpecifics Technologies Corp. To Present at BioCentury 'NewsMakers in the Biotech Industry' Conference
Date:9/11/2009

LYNBROOK, N.Y., Sept. 11 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that BioSpecifics' President, Tom Wegman, will present at the upcoming BioCentury "NewsMakers in the Biotech Industry" Conference on Wednesday, September 16, 2009, at 9:00 am ET at the Millennium Broadway Hotel & Conference Center in New York, NY.

A live webcast of the presentation can be accessed under "Calendar of Events" in the Investor Relations section of the Company's website at www.biospecifics.com, or you may use the link: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=BSTC&item_id=2413263.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
3. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
4. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
5. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
6. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
7. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
8. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
9. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
10. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
11. BioSpecifics Technologies Corp. Announces Appointment of Dr. Matthew Geller to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)...  At the 2017 Health Information Management Systems ... , IBM (NYSE: IBM ) today introduced ... President and CEO Ginni Rometty will ... 8:30-10 am ET, broadcast live on www.ibm.com ... examine the advent of the Cognitive Era and ...
(Date:2/18/2017)... 2017 Kurzlehrgang mit Fokus ... Zelltherapie-Studien, Poster legt metaproteomische Analyse des Darm-Mikrobioms bei Säuglingen ... ... Dr. Yoav Peretz , Scientific Director bei ImmuneCarta, ... Assays zum Nachweis intrazellulärer Zytokine bei adoptiven Zelltherapie-Studien im ...
(Date:2/18/2017)... DUBLIN , Feb 17, 2017 Research ... Global Strategic Business Report" report to their offering. ... The report provides separate ... Europe , and Rest of World. Annual estimates and ... six-year historic analysis is provided for these markets. Market data and ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
Breaking Biology Technology:
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/24/2017)... , Jan. 24, 2017 Biopharm ... of the laboratory use of nuclear magnetic resonance ... experienced end-users and profiled current practices, developments, trends ... as well as growth and opportunities. These areas ... suppliers, NMR instruments, needs and innovation requirements, hyphenated ...
(Date:1/23/2017)... 2017  The latest mobile market research from Acuity ... dramatically. The quarterly average price of a biometric smartphone ... Q4 2016.  There are now 120 sub-$150 models on ... from just 28 a year ago at an average ... Maxine Most , Acuity Market Intelligence Principal, "Biometric Smartphones ...
Breaking Biology News(10 mins):